PhoenixBio Co., Ltd. (TYO:6190)

PhoenixBio Revenue

In the fiscal year ending March 31, 2026, PhoenixBio had annual revenue of 1.57B JPY with 1.56% growth. PhoenixBio had revenue of 365.00M in the quarter ending March 31, 2026, a decrease of -8.29%.

• Revenue: 1.57B
• Revenue Growth: +1.56%
• P/S Ratio: 1.02
• Revenue / Employee: 22.68M
• Employees: 69
• Market Cap: 1.59B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	1.57B	24.00M	1.56%
Mar 31, 2025	1.54B	-174.00M	-10.15%
Mar 31, 2024	1.72B	-409.00M	-19.26%
Mar 31, 2023	2.12B	800.00M	60.42%
Mar 31, 2022	1.32B	311.00M	30.70%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 1, 2026

Data Sources Report a data error